The stock's fall snapped a two-day winning streak.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.

This was the stock's second consecutive day of gains.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $93.07 which represents a slight increase of $0.15 or 0.16% from the prior close of $92.92. The stock opened at $92.36 and ...

Congestive Heart Failure Treatment Market Predicted Growth At 4.47% CAGR To 35.5 Billion USD By 2032 Gilead Sciences The Global Congestive Heart Failure Treatment market is witnessing significant ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...